Linking real-world data with commercial patient access programs: A strategy for enhanced insights into factors that impact patient access and adherence to therapy
UBC’s approach to real-world data tokenization and linkage enhances study results with longitudinal observation of various participant health outcomes during the pre-and post-trial period.
Longitudinal Real-World Data: How to Gain Deeper Insights Into Your Clinical Studies
Linking longitudinal real-world data (RWD) to clinical study data offers deeper insights for drug developers. Contextualize study outcomes, extend data collection after the study ends, close the efficacy-effectiveness gap, and identify post-market patterns.
Evolving PV Landscape: Artificial Intelligence and Advanced Gene Therapy
UBC Pharmacovigilance experts, Dobrochna Dolicka, Christopher Henry, Alix Garcia and Irene Navarro presented at DIA Europe 2025 on how AI can be used to streamline pharmacovigilance activities and how harmonization of guidelines can be enhanced in order to define a specific framework for gene therapy.
Unlocking the Potential of Psychedelic Therapies
Psychedelic-assisted therapies are starting to emerge with potential as treatments for mental health conditions. Explore the evidence behind an increased interest in this use of substances such as psilocybin, MDMA, LSD, and DMT, and the future of research in this area.
The Crucial Role of Adherence Support for Patients Prescribed a High-Cost Injectable or Infusion Therapy
Adherence is critical to ensuring patients receive full therapeutic benefit and effectively manage their disease, particularly for complex treatments such as injectables or infusions. Explore strategies to support patients and improve adherence in the blog.
Global Risk Management and Risk Evaluation and Mitigation Strategy (REMS) Developments in 2024 and Considerations for 2025
Dive deep on a number of developments occurred during 2024 that will drive considerations in risk management and REMS for 2025 and beyond.
Driving Program Awareness through Stakeholder Collaboration
This article explores strategies to enhance Patient Service Programs (PSPs) awareness through digital engagement and provider collaboration.
Standardization and the Evolving REMS Landscape
Learn about the FDA’s new guidance, the challenges of standardization, and how UBC is driving innovation in REMS implementation using modern APIs from UBC’s VP of Data Intelligence and Program Analytics, Jim Shamp.
The Evolution of Patient Support for Cell and Gene Therapy Products
Discover UBC’s insights from the Cell & Gene Meeting on the Mesa, the unique challenges patients face, and the importance of tailored support services to ensure successful treatment journeys
